Ogurtsova K,da Rocha Fernandes JD,Huang Y,Linnenkamp U,Guariguata L,Cho NH .2017 .IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract, 03 : 40-50.
Jr Custodio,Duraes AR,Abreu M,Albuquerque Rocha N,Roever L .2018 .SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev, 23(3) : 409-18.
Lehrke M,Marx N. .2017 .Diabetes mellitus and heart failure. Am J Med, 04(6S) : S40-S50.
Martens P,Mathieu C,Verbrugge FH .2017 .Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med, 19(3) : 23.
Zinman B,Wanner C,Lachin JM,Fitchett D,Bluhmki E,Hantel S .2015 .Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 373(22) : 2117-28.
Scirica BM,Bhatt DL,Braunwald E,Steg PG,Davidson J,Hirshberg B .2013 .Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 369(14) : 1317-26.
Vallon V,Platt KA,Cunard R,Schroth J,Whaley J,Thomson SC .2011 .SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol, 22(1) : 104-12.
DeFronzo RA,Norton L,Abdul-Ghani M .2016 .Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol, 13(1) : 11-26.
Rahmoune H,Thompson PW,Ward JM,Smith CD,Hong G,Brown J .2005 .Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. 54.12.3427, 54(12) : 3427-34.
Rossetti L,Smith D,Shulman GI,Papachristou D,DeFronzo RA .1987 .Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest, 79(5) : 1510-5.
Abdul-Ghani MA,DeFronzo RA,Norton L .2013 .Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes, 62(10) : 0604-8.
Hadjadj S,Rosenstock J,Meinicke T,Woerle HJ,Broedl UC .2016 .Initial combination of empagliflozin and metformin in patients with type 2 diabetes. Diabetes Care, 39(10) : 0522-28.
Pham SV,Chilton R.,EMPA-REG OUTCOME .2017 .The cardiologist's point of view. Am J Med, 04(6S) : S57-S62.
de Boer IH,Bangalore S,Benetos A,Davis AM,Michos ED,Muntner P .2017 .Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care, 40(9) : 0026-84.
Mazidi M,Rezaie P,Gao HK,Kengne AP .2017 .6(6): e004007. J Am Heart Assoc, : .
Weber MA,Mansfield TA,Cain VA,Iqbal N,Parikh S,Ptaszynska A .2016 .Blood pressure and glycaemic efects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebocontrolled, phase 3 study. Lancet Diabetes Endocrinol, 8587(15) : 00417-9.
Kario K,Böhm M,Mahfoud F,Townsend RR,Weber MA,Patel M .2018 .Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 138(15) : 1602-4.
Chilton R,Tikkanen I,Cannon CP,Crowe S,Woerle HJ,Broedl UC .2015 .Efects of empagliflozin on blood pressure and markers of arterial stifness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab, 17(12) : 1180-93.
Lopaschuk GD,Ussher JR,Folmes CD,Jaswal JS,Stanley WC .2010 .Myocardial fatty acid metabolism in health and disease. Physiol Rev, 90(1) : 207-58.
AbouEzzeddine OF,Kemp BJ,Borlaug BA,Mullan BP,Behfar A,Pislaru SV .2019 .: e006240. Circ Heart Fail, 12(10) : .
Ferrannini E,Muscelli E,Frascerra S,Baldi S,Mari A,Heise T .2014 .Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest, 124(2) : 499-508.
Ferrannini E,Baldi S,Frascerra S,Astiarraga B,Heise T,Bizzotto R .2016 .Shift to fatty substrate utilization in response to sodiumglucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes, 65(5) : 1356-5.
Verma S,Rawat S,Ho KL,Wagg CS,Zhang L,Teoh H .2018 .Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl Sci, 07(5) : 575-87.
Santos-Gallego CG,Requena-Ibanez JA,Ishikawa K,Watanabe S,Picatoste B .2019 .Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol, 01(15) : 1931-44.
Dick SA,Epelman S. .2016 .Chronic heart failure and inflammation: what do we really know?. Circ Res, 119(1) : 159-76.
Mehta JL,Pothineni NV .2016 .Inflammation in heart failure: the holy grail. Hypertension, 68(1) : 27-9.
Briasoulis A,Androulakis E,Christophides T,Tousoulis D. .2016 .The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev, 21(2) : 169-76.
Butts B,Gary RA,Dunbar SB,Butler J. .2015 .The importance of NLRP3 inflammasome in heart failure. J Card Fail, 04(7) : 586-93.
Eslick GD,Thampan BV,Nalos M,McLean AS,Sluyter R.,Circulating R. .2008 .-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int J Cardiol, 05(1) : 81-3.
Otani H. .2009 .The role of nitric oxide in myocardial repair and remodeling. Antioxid Redox Signal, 11(8) : 1913-28.
Vaduganathan M,Greene SJ,Butler J,Sabbah HN,Shantsila E,Lip GYH .2013 .The immunological axis in heart failure: importance of the leukocyte diferential. Heart Fail Rev, 18(6) : 835-45.
Kim SR,Lee SG,Kim SH,Kim JH,Choi E,Cho W .2020 .SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun, 11(1) : 2127.
Bolinder J,Ljunggren Ö,Kullberg J,Johansson L,Wilding J,Langkilde AM .2012 .Efects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab, 97(3) : 2260-31.
Ferrannini G,Hach T,Crowe S,Sanghvi A,Hall KD,Ferrannini E .2015 .Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care, 38(9) : 0355-5.
Lee PC,Ganguly S,Goh SY .2018 .Weight loss associated with sodiumglucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes Rev, 19(12) : 1630-41.
Sano M. .2017 .A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol, 12(5) : 471-6.
Sano M. Hemodynamic .2017 .Efects of Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Med Res, 9(6) : 457-60.
Sano M,Chen S,Imazeki H,Ochiai H,Seino Y. .2018 .Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig, 9(3) : 638-41.
Pabel S,Hamdani N,Luedde M,Sossalla S. .2021 .SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled?. Curr Heart Fail Rep, 18(5) : 315-28.
Grubić Rotkvić P,Cigrovski Berković M,Bulj N,Rotkvić L .2020 .Minireview: are SGLT2 inhibitors heart savers in diabetes?. Heart Fail Rev, 25(6) : 899-905.
Yancy CW,Jessup M,Bozkurt B,Butler J,Casey DE,Drazner MH .2013 .ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol, 05(16) : e147-239.
Felker GM,Thompson RE,Hare JM,Hruban RH,Clemetson DE,Howard DL .2000 .Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med, 342(15) : 1077-84.
Passino C,Barison A,Vergaro G,Gabutti A,Borrelli C,Emdin M .2014 .Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta, 09 : 29-38.
Zhou H,Wang S,Zhu P,Hu S,Chen Y,Ren J .2017 .Empagliflozin rescues diabetic myocardial microvascular injury via AMPKmediated inhibition of mitochondrial fission. Redox Biol, 12 : 335-46.
Bailey CJ .2019 .Uric acid and the cardio-renal efects of SGLT2 inhibitors. Diabetes Obes Metab, 21(6) : 1291-8.
Lytvyn Y,Perkins BA,Cherney DZ .2014 .Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes, 10(3) : 239-46.
Zhao Y,Xu L,Tian D,Xia P,Zheng H,Wang L .2018 .Efects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab, 20(2) : 458-62.
Lambers Heerspink HJ,de Zeeuw D,Wie L,Leslie B,List J.,Dapagliflozin J. .2013 .a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab, 15(9) : 853-62.
Hallow KM,Helmlinger G,Greasley PJ,McMurray JJV,Boulton DW .2018 .Why do SGLT2 inhibitors reduce heart failure hospitalization? A diferential volume regulation hypothesis. Diabetes Obes Metab, 20(3) : 479-87.